跳至主要内容
临床试验/TCTR20210209002
TCTR20210209002尚未招募3 期

A randomized double blinded placebo controlled trial of prophylactic rectal indomethacin for prevention of postembolization syndrome in Patients with hepatocellular carcinoma

In process for Ratchadaphiseksomphot Endowment Fund submission0 个研究点目标入组 120 人开始时间: 2021年2月9日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • Patients with intermediate stage (B) HCC eligible for TACE according to the latest (2018) EASL Clinical Practice Guideline in Management of Hepatocellular Carcinom

排除标准

  • Serum Cr > 1.4 mg/dl
  • Recent GI bleeding within 4 weeks
  • Allergy to NSAIDs or aspirin
  • Concomittent use of oral NSAIDs, steroid within 1 week

研究者

发起方
In process for Ratchadaphiseksomphot Endowment Fund submission

相似试验

A Randomized Double-blinded Placebo-controlled Trial... | 临床试验